Comparative bioavailability of sustained-release and uncoated aspirin tablets. 1981

W J Karahalios, and W T Sawyer, and R A Rittase, and S A Maynard

Plasma salicylate concentrations during multiple-dose administration of an uncoated and a sustained-release aspirin preparation were compared. Eight healthy adult subjects were given aspirin 2.6 g/day as sustained-release and uncoated tablets in two and four divided doses, respectively, for five-day periods in a crossover design. Treatment regimens were compared on the basis of five plasma salicylate concentrations measured during the fourth and fifth days of drug administration. Although there was considerable intersubject variation, no significant differences in salicylate concentrations (p less than or equal to 0.05) were found between treatments at any sampling time using the Wilcoxon signed-rank test or analysis of variance. Sustained-release aspirin preparations are capable of producing plasma salicylate concentrations comparable with those produced by uncoated aspirin tablets administered more frequently.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001241 Aspirin The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) Acetylsalicylic Acid,2-(Acetyloxy)benzoic Acid,Acetysal,Acylpyrin,Aloxiprimum,Colfarit,Dispril,Easprin,Ecotrin,Endosprin,Magnecyl,Micristin,Polopirin,Polopiryna,Solprin,Solupsan,Zorprin,Acid, Acetylsalicylic
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D012459 Salicylates The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis. Salicylate,Salicylic Acids,Acids, Salicylic
D013607 Tablets Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed) Tablet

Related Publications

W J Karahalios, and W T Sawyer, and R A Rittase, and S A Maynard
December 1980, American journal of hospital pharmacy,
W J Karahalios, and W T Sawyer, and R A Rittase, and S A Maynard
July 2012, Arzneimittel-Forschung,
W J Karahalios, and W T Sawyer, and R A Rittase, and S A Maynard
March 1986, Clinical pharmacy,
W J Karahalios, and W T Sawyer, and R A Rittase, and S A Maynard
September 1979, International journal of clinical pharmacology and biopharmacy,
W J Karahalios, and W T Sawyer, and R A Rittase, and S A Maynard
November 1977, European journal of clinical pharmacology,
W J Karahalios, and W T Sawyer, and R A Rittase, and S A Maynard
January 1979, European journal of clinical pharmacology,
W J Karahalios, and W T Sawyer, and R A Rittase, and S A Maynard
January 1998, European journal of drug metabolism and pharmacokinetics,
W J Karahalios, and W T Sawyer, and R A Rittase, and S A Maynard
September 2011, Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition,
W J Karahalios, and W T Sawyer, and R A Rittase, and S A Maynard
January 2006, European journal of drug metabolism and pharmacokinetics,
W J Karahalios, and W T Sawyer, and R A Rittase, and S A Maynard
October 1991, Pharmaceutical research,
Copied contents to your clipboard!